Stocks News

LAST PRICE
486.1100
TODAY'S CHANGE (%)
Trending Down-1.2600 (-0.2585%)

Bid / Lots
485.0200/ 1
Ask / Lots
491.8500/ 1
Open / Previous Close
489.2700 / 487.3700
Day Range
Low 485.9700
High 491.8797
52 Week Range
Low 340.8300
High 510.6350
Volume
810,296
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Aug 19, 2024
- RMR Renews Boston Lease With Vertex Pharmaceuticals, from 10:54AM ET on Monday Aug 19, 2024 by MT Newswires
  10:54AM ET on Monday Aug 19, 2024 by MT Newswires
  Companies Mentioned: VRTX, RMR
  10:54 AM EDT, 08/19/2024 (MT Newswires) -- The RMR Group (RMR) said Monday that Vertex Pharmaceuticals (VRTX) has renewed its lease for properties in Boston. The lease for the 1.1-million-square-foot office and laboratory space at 50 Northern Ave. a...
Aug 12, 2024
- Vertex Pharmaceuticals Insider Sold Shares Worth $602,447, According to a Recent SEC Filing, from 4:15PM ET on Monday Aug 12, 2024 by MT Newswires
  4:15PM ET on Monday Aug 12, 2024 by MT Newswires
  Companies Mentioned: VRTX
  04:15 PM EDT, 08/12/2024 (MT Newswires) -- Sangeeta N. Bhatia, Director, on August 08, 2024, sold 1,292 shares in Vertex Pharmaceuticals (VRTX) for $602,447. Following the Form 4 filing with the SEC, Bhatia has control over a total of 4,435 shares o...
Aug 8, 2024
- Redburn Atlantic Adjusts Price Target on Vertex Pharmaceuticals to $560 From $545, from 10:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  10:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  Companies Mentioned: VRTX
  10:01 AM EDT, 08/08/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $600, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $550 From $540, from 10:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  10:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  Companies Mentioned: VRTX
  10:01 AM EDT, 08/08/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $600, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic...
- Vertex Pharmaceuticals Signs Reimbursement Deal in England for Transfusion-Dependent Beta Thalassemia Treatment, from 5:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  5:01AM ET on Thursday Aug 08, 2024 by MT Newswires
  Companies Mentioned: VRTX
  05:01 AM EDT, 08/08/2024 (MT Newswires) -- Vertex Pharmaceuticals (VRTX) said late Wednesday it signed a reimbursement agreement with NHS England to give eligible patients access to the company's Casgevy therapy for the treatment of transfusion-depe...

Yesterday
- Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA, from 10 hours ago by Accesswire
  10 hours ago by Accesswire
  Companies Mentioned: MRNA
- Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: MRNA
- MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!, from 10 hours ago by Newsfile
  10 hours ago by Newsfile
  Companies Mentioned: MRNA
- MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!, from 10 hours ago by Dow Jones
  10 hours ago by Dow Jones
  Companies Mentioned: MRNA
- Shareholders that lost money on Moderna, Inc. (MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA, from 13 hours ago by Accesswire
  13 hours ago by Accesswire
  Companies Mentioned: MRNA
- Shareholders that lost money on Moderna, Inc. (MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: MRNA
- October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA, from 13 hours ago by GlobeNewswire
  13 hours ago by GlobeNewswire
  Companies Mentioned: MRNA
- October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: MRNA
- ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA, from 13 hours ago by Newsfile
  13 hours ago by Newsfile
  Companies Mentioned: MRNA
- ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA, from 13 hours ago by Dow Jones
  13 hours ago by Dow Jones
  Companies Mentioned: MRNA

Vertex Pharmaceuticals Inc
NASDAQ:VRTXUnited States

Search Criteria

Aug 19, 2024

RMR Renews Boston Lease With Vertex Pharmaceuticals, from 10:54AM ET on Monday Aug 19, 2024 by MT Newswires

Aug 12, 2024

Vertex Pharmaceuticals Insider Sold Shares Worth $602,447, According to a Recent SEC Filing, from 4:15PM ET on Monday Aug 12, 2024 by MT Newswires

Aug 8, 2024

Redburn Atlantic Adjusts Price Target on Vertex Pharmaceuticals to $560 From $545, from 10:01AM ET on Thursday Aug 08, 2024 by MT Newswires

Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $550 From $540, from 10:01AM ET on Thursday Aug 08, 2024 by MT Newswires

Vertex Pharmaceuticals Signs Reimbursement Deal in England for Transfusion-Dependent Beta Thalassemia Treatment, from 5:01AM ET on Thursday Aug 08, 2024 by MT Newswires

Peers Headlines

Yesterday

Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA, from 10 hours ago by Accesswire

Levi & Korsinsky Reminds Moderna Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 8, 2024 - MRNA, from 10 hours ago by Dow Jones

MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!, from 10 hours ago by Newsfile

MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!, from 10 hours ago by Dow Jones

Shareholders that lost money on Moderna, Inc. (MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA, from 13 hours ago by Accesswire

Shareholders that lost money on Moderna, Inc. (MRNA) should contact Levi & Korsinsky about pending Class Action - MRNA, from 13 hours ago by Dow Jones

October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA, from 13 hours ago by GlobeNewswire

October 8, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRNA, from 13 hours ago by Dow Jones

ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA, from 13 hours ago by Newsfile

ROSEN, A LEADING LAW FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRNA, from 13 hours ago by Dow Jones